<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Adjuvant radiation therapy or chemoradiation in the management of head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Avraham Eisbruch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francis P Worden, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard V Smith, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall R Posner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Selected high-risk patients with head and neck squamous cell carcinoma receive adjuvant (ie, postoperative) radiation therapy (RT), with or without concurrent chemotherapy, following primary surgical resection with the aim of improving locoregional control and survival. The rationale for this approach is that RT may eradicate microscopic deposits of cancer cells that would progress and lead to a locoregional recurrence.</p><p>The role of adjuvant RT for head and neck cancer, usually given with concurrent chemotherapy, will be reviewed here. Other relevant topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a>.) </p><p></p><p class="headingAnchor" id="H862126779"><span class="h1">APPROACH TO ADJUVANT MANAGEMENT</span><span class="headingEndMark"> — </span>Patients who have undergone gross total resection of their primary tumor may be at high risk of recurrent disease, depending on the specific clinicopathologic features of their tumor. In this situation, adjuvant radiation therapy (RT), generally in conjunction with chemotherapy, can improve the likelihood of disease-free survival. The approach described below is in general agreement with guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) [<a href="#rid1">1-3</a>].</p><p>Adjuvant chemoradiation is generally restricted to patients thought to be at highest risk of locoregional recurrence. It should be used with caution and only in those at high risk because of the morbidity of adding chemotherapy to adjuvant RT and the uncertainty regarding a survival benefit [<a href="#rid4">4</a>]. RT alone remains an alternative for patients with intermediate levels of increased risk or for those who cannot tolerate concurrent chemotherapy.</p><p>Factors that have been associated with an increased risk of locoregional recurrence after surgery include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced tumor stage (T3/T4)</p><p class="bulletIndent1"><span class="glyph">●</span>Positive resection margins or tumor close to the resection margin</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor extension through the lymph node capsule (extranodal extension)</p><p class="bulletIndent1"><span class="glyph">●</span>Two or more pathologically positive lymph nodes</p><p class="bulletIndent1"><span class="glyph">●</span>Perineural invasion</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphovascular space invasion</p><p></p><p>Positive margins and extracapsular extension are the two most unfavorable parameters, both of which are associated with significant increases in locoregional recurrence and mortality [<a href="#rid5">5-8</a>]. These two features constitute the typical indication(s) for the addition of chemotherapy to RT. The definition of positive margins is not standardized; however, invasive tumor within 5 mm of the resection margin is commonly used [<a href="#rid9">9</a>]. Metastases in a single ipsilateral lymph node, 3 cm or less in greatest dimension (ie, N1 lymph node stage), is not considered a high-risk feature in the absence of other adverse factors [<a href="#rid10">10</a>].</p><p>Extranodal extension may also have prognostic significance in the patient with human papillomavirus (HPV) associated oropharyngeal cancer. Initial retrospective data suggested that extranodal extension is not a negative prognostic feature in these patients, not affecting disease-free or disease-specific survival [<a href="#rid11">11,12</a>], unlike carcinomas originating in the oral cavity and hypopharynx/larynx. However subsequent observational and prospective studies found that extranodal extension was associated with inferior survival in patients with HPV associated tumors [<a href="#rid13">13-15</a>]. Other traditional risk factors, advanced T stage and number of nodal metastases, were also associated with decreased survival. While clinical trial data evolves, it is important to maintain current adjuvant treatment protocols in those patients who will have a stage change under the eighth edition American Joint Committee on Cancer (AJCC) staging system for HPV associated oropharyngeal carcinoma  (<a class="graphic graphic_table graphicRef110641 graphicRef110640" href="/z/d/graphic/110641.html" rel="external">table 1A-B</a>).</p><p class="headingAnchor" id="H5"><span class="h1">ADJUVANT CHEMORADIATION</span><span class="headingEndMark"> — </span>Clinical trials have demonstrated that adjuvant concurrent chemoradiation is more likely than adjuvant radiation therapy (RT) alone to control locoregional disease and improve disease-free survival for patients at high risk of recurrent disease. Thus, we recommend adjuvant concurrent chemoradiation over adjuvant RT alone for patients at highest risk (ie, those with positive surgical margins and/or extranodal extension).</p><p class="headingAnchor" id="H6"><span class="h2">Chemoradiation versus radiation therapy alone</span><span class="headingEndMark"> — </span>Two cooperative group trials compared adjuvant chemoradiation with adjuvant RT alone and provide insights into which patient subsets benefit from a combined approach:</p><p class="bulletIndent1"><span class="glyph">●</span>In the European Organization for Research and Treatment of Cancer (EORTC) trial 22931, 334 patients with resected high-risk head and neck cancer were randomly assigned to RT alone (66 Gy in 33 daily 2 Gy fractions) or the same dose with concomitant <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (100 mg/m<sup>2</sup>, on days 1, 22, and 43 of RT) [<a href="#rid16">16</a>]. High-risk disease was defined as a T3 or T4 primary with any nodal stage (except T3N0 laryngeal cancer), positive surgical margins, extranodal extension, perineural invasion, vascular invasion, or oral cavity/oropharyngeal primary sites with involvement of level IV or V lymph nodes. With a median follow-up of 60 months, adjuvant concurrent chemoradiation significantly improved five-year progression free survival, locoregional control, and overall survival compared with adjuvant RT alone (47 versus 36 percent, 82 versus 69 percent, and 53 versus 40 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Radiation Therapy Oncology Group (RTOG) 9501 trial randomly assigned 459 patients with resected high-risk head and neck cancer to RT alone (60 to 66 Gy in 30 to 33 fractions) or the same dose of RT with concomitant <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (100 mg/m<sup>2</sup>, on days 1, 22, and 43 of RT) [<a href="#rid17">17</a>]. High-risk patients were limited to those with positive resection margins, involvement of two or more lymph nodes, or extranodal extension. In an initial report with a median follow-up of 46 months, concurrent chemoradiation improved two-year locoregional control and disease-free survival compared with RT alone (82 versus 72 percent and 54 versus 45 percent, respectively). However, the increase in overall survival was not statistically significant (64 versus 57 percent).</p><p></p><p>In both trials, the incidence of acute severe mucosal toxicity was significantly greater with adjuvant concurrent chemoradiation compared with RT alone (77 versus 34 percent in the EORTC trial), but late complications were comparable for both treatments.</p><p>The failure of these two trials to reach the same conclusion (ie, that concurrent chemoradiation improves locoregional control, disease-free survival, and overall survival) has been attributed to the different patient populations included in these two trials [<a href="#rid4">4,18</a>]. When comparative analyses were performed on pooled data from these trials (including selection criteria, clinical and pathologic risk factors, and treatment outcomes), extranodal extension and microscopically involved surgical margins were the only risk factors for which the impact of adjuvant concurrent chemoradiation was significant in both trials [<a href="#rid18">18</a>].</p><p>In extended follow-up of RTOG 9501 at 10 years, compared with RT alone, chemoradiation did not improve locoregional failure (22 versus 29 percent), disease-free survival (20 versus 19 percent), or overall survival (29 versus 27 percent) [<a href="#rid19">19</a>]. However, in an unplanned subgroup analysis of patients with extranodal spread or positive margins, chemoradiation improved locoregional control and disease-free survival and trended towards improved overall survival.</p><p>Consequently, we and others recommend adjuvant concurrent chemoradiation over adjuvant RT alone primarily for patients with positive surgical margins and/or extranodal extension [<a href="#rid18">18,20</a>]. Whether concurrent chemoradiation should be routinely added to adjuvant RT for patients with locoregionally advanced head and neck cancer and other adverse features is less clear. However, one large retrospective study suggests the effects of adjuvant chemoradiation on overall survival differed according to the number of positive lymph nodes, with the greatest absolute benefit in patients with two to four, or five or greater lymph nodes [<a href="#rid21">21</a>]. chemoradiation</p><p>Patients at elevated risk for recurrence based on perineural or vascular invasion, two or more involved lymph nodes, or T3 and T4 tumors are considered to be at intermediate risk and are commonly treated with adjuvant RT alone. The phase III RTOG 0920 trial is comparing RT alone versus RT plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> in patients with intermediate risk disease (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00956007%3Fterm%3DNCT00956007%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSy6SK%2BKLScyZWFvWcVyQ2oiuT61hy7%2BmH2s6%2Fxyf2vFQFPMcskgiQH7u6JBE20clYI%3D&amp;TOPIC_ID=3374" target="_blank">NCT00956007</a>). Likewise, the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) Cancer Research Group phase III trial is comparing RT alone with RT plus weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in patients with disruptive p53 mutations after primary surgical resection with negative surgical margins, no extranodal extension, and no gross residual disease (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02734537%3Fterm%3DNCT02734537%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOrArOvMxL50wmteZ2aosLyeTVTl0ziEp2Go1N02dxikylyo9Q2z9hihv4AiDK4zAU%3D&amp;TOPIC_ID=3374" target="_blank">NCT02734537</a>). (See <a class="local">'Adjuvant radiation therapy alone'</a> below.)</p><p>It is also important to note the primary site of disease, such as human papillomavirus (HPV) associated oropharyngeal cancer. The approach to adjuvant RT and chemoradiation in these patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Adjuvant RT with or without chemotherapy'</a>.)</p><p>It has not been clearly established in prospective clinical trials that adjuvant chemoradiation provides greater benefit than RT alone in HPV associated head and neck cancer. A randomized trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01687413%3Fterm%3DNCT01687413%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzsJf3If9Fs1BlUGXQoEBcWg%2BUSg22rC%2FGkjvTElz7AiD69sYPYmGPhQpoW1M6xS1o%3D&amp;TOPIC_ID=3374" target="_blank">NCT01687413</a>) attempted to answer this question, but was terminated due to poor accrual and funding issues. Further details on clinical trials evaluating treatment deintensification in HPV associated oropharyngeal cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Is there a role for treatment deintensification?'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Concurrent chemotherapy regimen</span></p><p class="headingAnchor" id="H2352978061"><span class="h3">Platinum-based chemotherapy</span></p><p class="headingAnchor" id="H3500751625"><span class="h4">Cisplatin</span><span class="headingEndMark"> — </span>For patients who are eligible for platinum-based chemotherapy, we recommend administering weekly dosing of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (40 mg/m<sup>2</sup> weekly) rather than bolus dosing (100 mg/m<sup>2</sup> every 21 days for three cycles) concurrently with adjuvant RT. In a randomized trial, weekly cisplatin demonstrated non-inferior overall survival and an improved toxicity profile when compared with bolus cisplatin [<a href="#rid22">22</a>]. Bolus dosing of cisplatin is associated with considerable severe acute and late toxicities and is no longer the preferred regimen for patients receiving adjuvant chemoradiation [<a href="#rid16">16,17</a>].</p><p>For patients who are ineligible for cisplatin-based chemotherapy, we suggest treatment with RT alone rather than concurrent chemoradiation with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. (See <a class="local">'Carboplatin'</a> below.)</p><p>While previous randomized studies suggested potential clinical benefit for weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in patients receiving adjuvant chemoradiation [<a href="#rid23">23-25</a>], the cisplatin dosing in these studies were not consistent (ranging between 30 mg/m<sup>2</sup> to 50 mg/m<sup>2</sup> weekly). Additionally, one randomized study of chemoradiation in the adjuvant setting did not confirm superior locoregional control with weekly cisplatin compared with bolus cisplatin [<a href="#rid26">26</a>]. However, this study consisted exclusively of patients with oral cavity disease, limiting its applicability to other disease sites, and demonstrated more toxicity for the bolus regimen. </p><p>The clinical benefits of weekly dosing of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> at 40 mg/m<sup>2</sup> were confirmed in an open label phase II/III trial (JCOG1008) of 261 patients with resected high-risk pathologic AJCC seventh edition stage III-IVB disease (eg, positive surgical margins and/or extranodal extension). Patients enrolled had primary tumors of the oral cavity, larynx, oropharynx, or hypopharynx; notably, approximately half (121 patients) had oral cavity primary tumors. In this study, patients were randomly assigned to adjuvant chemoradiation (66 Gy) with either weekly cisplatin (40 mg/m<sup>2</sup> weekly for six to seven doses) or bolus cisplatin (100 mg/m<sup>2</sup> every three weeks) [<a href="#rid22">22</a>]. At median follow-up of 2.2 years, compared with bolus cisplatin, weekly cisplatin demonstrated non-inferior overall survival (OS), relapse-free survival (RFS), and local relapse-free survival (LRFS) at three years (OS, 72 versus 59 percent, HR 0.69, 95% CI 0.37-1.27; RFS, 64 versus 53 percent, HR 0.71, 95% CI 0.48-1.06; LRFS 70 versus 60 percent, HR 0.73, 95% CI 0.47-1.13). Both groups achieved the crucial cumulative cisplatin dose ≥200 mg/m<sup>2</sup> (230 versus 280 mg/m<sup>2</sup>), as data suggest this threshold is more effective than lower cumulative doses, when given concurrently with RT [<a href="#rid27">27-29</a>].</p><p>Weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> had a more favorable toxicity profile compared with bolus cisplatin, which is associated with severe acute and late toxicities [<a href="#rid16">16,17</a>]. Grade ≥3 toxicities were lower in the weekly cisplatin group than the bolus cisplatin group, including neutropenia (35 versus 49 percent), dysphagia (12 versus 18 percent), nausea (5 versus 13 percent), and infection (7 versus 12 percent). Specific platinum-related toxicity of any grade were also lower in the weekly cisplatin group, including hyponatremia (82 versus 92 percent), renal impairment (30 versus 40 percent), hearing impairment (7 versus 17 percent), and peripheral neuropathy (2 versus 5 percent). </p><p>The use of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> as a chemosensitizing agent in patients receiving definitive chemoradiation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Cisplatin'</a>.)</p><p class="headingAnchor" id="H579025283"><span class="h4">Carboplatin</span><span class="headingEndMark"> — </span>For patients are ineligible for cisplatin-based therapy, we suggest treatment with RT alone rather than alternative platinum agents (eg, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>), particularly for those who are ineligible due to age, comorbidities, and/or performance status. While we offer this same approach to those who are ineligible for cisplatin-based therapy due to other conditions (eg, kidney disease, neuropathy, sensorineural hearing loss, congestive heart failure) but otherwise have good performance status or minimal comorbidities, the additive benefit of other chemosensitizing regimens to RT remains under investigation. (See <a class="local">'Other regimens'</a> below.)</p><p>When <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> (50 mg/m<sup>2</sup> twice weekly) rather than <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> was used as the concurrent chemotherapy in a clinical trial of patients with lymph node-positive head and neck cancer, no significant improvement in locoregional control or overall survival was seen compared with RT alone [<a href="#rid30">30</a>]. Whether this was due to the chemotherapy regimen or other factors, such as patient selection, is unclear.</p><p>The approach to the optimal chemotherapy regimen in patients receiving definitive concurrent chemoradiation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Concurrent chemotherapy'</a>.)</p><p class="headingAnchor" id="H373586612"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>Both weekly <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> have demonstrated activity in patients with head and neck cancer in other clinical settings and are being investigated as alternatives to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in the adjuvant setting.</p><p class="headingAnchor" id="H8"><span class="h4">Cetuximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a>, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has established efficacy when given concurrently with RT, as opposed to RT alone, in the primary treatment of locoregionally advanced head and neck cancer not including the oral cavity. However, the role of cetuximab is not established in the adjuvant setting and should only be used as part of an adjuvant strategy in the context of a clinical trial. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Cetuximab plus radiation therapy'</a>.)</p><p>In a randomized phase II trial, patients were randomly assigned to weekly low-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or weekly <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> plus cetuximab following gross total resection of tumor [<a href="#rid25">25,31</a>]. Both combinations were feasible, with expected increased toxicity attributable to the addition of cetuximab and favorable outcomes compared with historical controls. In addition, the trial provided preliminary evidence that taxanes may be as effective as cisplatin in head and neck cancer.</p><p>Phase III clinical trials assessing the role of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>RTOG 0920, in which patients with intermediate-risk locally advanced, resected head and neck cancer are being randomly assigned to adjuvant intensity-modulated RT (IMRT) with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01311063%3Fterm%3DNCT%2B01311063&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzsJf3If9Fs1BlUGXQoEBcW1dsX1YTRwm5SSPxqvq936BC%2BmLC2Zs%2B9uhqSF9bJmsE%3D&amp;TOPIC_ID=3374" target="_blank">NCT 01311063</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RTOG 1216, in which patients with high-risk, locally advanced, resected head and neck cancer are being randomly<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fhome&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwuWtJJ1t4oE0BLDg9oAHmh&amp;TOPIC_ID=3374" target="_blank">https://www.clinicaltrials.gov/ct2/home</a> assigned to IMRT plus weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, IMRT plus weekly <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, or weekly cisplatin plus <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01810913%3Fterm%3DNCT01810913%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzNnmqwgolanAVBrU0knN54cra7siKYwailwGRZPPZz4FlkO2BF07Uq8VosCjvC5Ao%3D&amp;TOPIC_ID=3374" target="_blank">NCT01810913</a>).</p><p></p><p class="headingAnchor" id="H2352978311"><span class="h4">Docetaxel</span><span class="headingEndMark"> — </span>Weekly <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, in conjunction with weekly <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, has been studied as a concurrent regimen with adjuvant RT in patients with high-risk head and neck cancer. Results from the randomized phase II RTOG 0234 study have suggested that this may be an alternative to <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>; RT concomitantly given with weekly docetaxel in combination with cetuximab is being compared against a weekly cisplatin regimen and a weekly cisplatin in combination with <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> regimen in the phase II/III RTOG 1216 trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01810913%3Fterm%3DNCT01810913%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzNnmqwgolanAVBrU0knN54cra7siKYwailwGRZPPZz4FlkO2BF07Uq8VosCjvC5Ao%3D&amp;TOPIC_ID=3374" target="_blank">NCT01810913</a>).</p><p class="headingAnchor" id="H2352977931"><span class="h1">ADJUVANT RADIATION THERAPY ALONE</span><span class="headingEndMark"> — </span>Adjuvant radiation therapy (RT) without concurrent chemotherapy is inferior to concurrent chemoradiation following gross tumor resection for high-risk disease. However, RT alone may retain a role for patients with intermediate-risk disease and for those whose overall condition cannot tolerate a concurrent therapy.</p><p>Data supporting the use of adjuvant RT without concurrent chemotherapy to improve locoregional control and survival are limited to two randomized trials and retrospective observational data:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial of 51 patients with advanced head and neck cancer found that the addition of RT to surgery decreased the overall recurrence rate [<a href="#rid32">32</a>]. However, no difference in overall survival was observed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second trial, limited to 140 patients, all with squamous cell carcinoma of the buccal mucosa, did observe a statistically significant increase in disease-free survival at three years with adjuvant RT compared with surgery alone [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective studies suggest that adjuvant RT improves survival after surgery, although this benefit may be limited to carefully selected high-risk patients. As an example, a Surveillance, Epidemiology and End Results (SEER) database study analyzed outcomes in 8795 patients with lymph node-positive head and neck cancer diagnosed between 1988 and 2001 [<a href="#rid34">34</a>]. All patients were treated with surgery and RT or surgery alone. On univariate analysis, the addition of adjuvant RT to surgery was associated with a significantly improved five-year overall survival (43.2 versus 33.4 percent) and cancer-specific survival (50.9 versus 42.1 percent). More detailed analyses of other observational series also support a role for adjuvant RT [<a href="#rid35">35,36</a>].</p><p></p><p>Adjuvant RT can cause important acute and late toxicity, which is related to the dose of radiation. For example, in a series of patients treated with either lower dose (57.6 Gy over 6.5 weeks) or higher dose (63 Gy over five weeks) adjuvant RT, confluent mucositis was present in the low- and high-dose cohorts in 5 and 47 percent of patients, and tube feeding was required in 12 and 39 percent of patients, respectively [<a href="#rid37">37</a>]. In addition, the five-year actuarial rates of late grade 3 and 4 toxicity (ulcer/soft tissue necrosis, fibrosis, dysphagia, fistula/osteonecrosis) were 17 and 38 percent for the low- and high-dose groups. (See  <a class="medical medical_review" href="/z/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment"</a>.)</p><p>Additional data may be derived from the phase III Radiation Therapy Oncology Group (RTOG) 0920 trial, which is comparing RT alone with RT plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> in patients with intermediate-risk disease (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00956007%3Fterm%3DNCT00956007%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSy6SK%2BKLScyZWFvWcVyQ2oiuT61hy7%2BmH2s6%2Fxyf2vFQFPMcskgiQH7u6JBE20clYI%3D&amp;TOPIC_ID=3374" target="_blank">NCT00956007</a>), or from EA3132, which is comparing RT alone with weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus RT in patients with disruptive p53 mutations (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02734537%3Fterm%3DEA3132%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOrArOvMxL50wmteZ2aosLyFhbKSU5F%2FSo4LEjFt%2BPJK6uBmzNFSy%2BSrZM9I%2BuGEw4%3D&amp;TOPIC_ID=3374" target="_blank">NCT02734537</a>).</p><p class="headingAnchor" id="H9"><span class="h1">ADMINISTRATION</span><span class="headingEndMark"> — </span>The total dose, timing, and duration of therapy may all affect outcomes in patients with head and neck squamous cell carcinoma receiving adjuvant radiation therapy (RT) or concurrent chemoradiation [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Initiation and treatment delays</span><span class="headingEndMark"> — </span>In the absence of wound healing issues or medical contraindications, adjuvant RT should be started no later than six weeks after surgery and should be completed in a timely manner.</p><p>The time interval between surgery and initiation of RT as well as the duration of adjuvant RT also appear to have an impact on outcome [<a href="#rid37">37-39</a>]. Patients who begin RT more than six weeks after surgery are more likely to develop a local recurrence [<a href="#rid38">38</a>]. Locoregional control is also better for patients who complete adjuvant RT within 100 days or less from the date of surgery compared with patients treated over a longer period of time [<a href="#rid37">37,39</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Dose and treatment volume</span><span class="headingEndMark"> — </span>The treatment parameters of adjuvant RT for head and neck cancer vary with the clinical and pathologic findings. (See  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Paradigms of dose and fractionation modification'</a>.)</p><p>If all gross disease is resected with negative surgical margins in patients with advanced primary lesions (T3/4), adjuvant RT doses of 56 to 60 Gy to the primary tumor bed are recommended. For patients with microscopically positive margins or extracapsular extension, a 6 Gy boost in three fractions for a total dose of 66 Gy to that region is recommended. For those with grossly positive margins, the site of residual disease should be boosted to a total dose of 70 Gy.</p><p>Patients with high-risk features (positive surgical margins, extranodal extension) who are not candidates for adjuvant concurrent chemoradiation are treated with doses of at least 60 Gy. Dose-response relationships are less well understood when concurrent chemotherapy is utilized, but most high-risk volumes typically receive doses ≥60 Gy in 2 Gy daily fractions.</p><p>The neck is usually included with adjuvant RT. A notable exception is that the neck is not included when treating patients with oral cancer in which the primary tumor has no high-risk characteristics and is either pathologically node negative or has a single pathologically positive node without adverse features after high-quality neck dissection. </p><p>Subclinical regions (ie, clinically negative neck) that have not been dissected are electively treated to the equivalent of 50 Gy in 25 fractions, which would be 54 Gy if 30 fractions are delivered at 1.8 Gy per fraction to the dissected neck. Operated but non-tumor-bearing areas typically receive 56 to 57 Gy. Involved nodal regions receive 60 Gy in 30 fractions, and regions of extranodal extension may receive an additional boost of 4 to 6 Gy in two to three fractions.</p><p>In an early clinical trial that aimed to establish the optimal dosing for conventionally fractionated adjuvant RT and that provided the initial evidence for a dose-response relationship, 261 evaluable patients were randomly assigned to one of three dose levels (57.6, 63, or 68.3 Gy, all given with 1.8 Gy/day fractionation) [<a href="#rid7">7,40</a>]. In an initial interim analysis, 17 patients treated with a dose of ≤54 Gy had a significantly higher primary failure rate compared with those treated with higher doses, and that group was dropped from the trial. In a final analysis with more than 20 years follow-up, no significant dose response was demonstrated at doses ≥57.6 Gy in the final analysis in either the intermediate- or high-risk groups. On multivariate analysis, negative surgical margins, the absence of extracapsular extension, and total treatment time &lt;85 days were independently associated with better locoregional control and overall survival. However, it is important to note that many of the high-risk patients included in this trial would receive concurrent chemoradiation in the contemporary treatment era, and it is therefore difficult to know how these data apply to such patients. </p><p class="headingAnchor" id="H13"><span class="h2">Schedule</span><span class="headingEndMark"> — </span>Conventional adjuvant RT schedules typically deliver 54 to 66 Gy in 2 Gy daily fractions, over five to seven weeks.</p><p>Altered-fractionation RT schedules, including accelerated RT and hyperfractionation, have been investigated to overcome accelerated repopulation and to safely escalate the dose. These strategies when compared with conventional, once-daily RT have demonstrated improved locoregional control, but a survival benefit has not been established [<a href="#rid41">41-43</a>]. The added cost and logistical challenges of multiple fractions per day RT have limited their implementation. (See  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Hyperfractionation'</a> and  <a class="medical medical_review" href="/z/d/html/3409.html" rel="external">"Definitive radiation therapy for head and neck cancer: Dose and fractionation considerations", section on 'Accelerated fractionation RT'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Radiation therapy techniques</span><span class="headingEndMark"> — </span>A standard approach for patients treated with adjuvant RT is to use conventional fractionation external beam RT (EBRT) using three-dimensional conformal treatment planning (3D-CRT). Intensity-modulated RT (IMRT) and refinements, such as image-guided RT (IGRT), are used wherever available. The dosimetric advantages of protons over IMRT in the treatment of head and neck cancer are related to reduced doses to noninvolved tissues, but controlled trials comparing observer and patient-reported outcomes in the adjuvant setting are lacking [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer", section on 'External beam radiation therapy'</a>.)</p><p>3D-CRT usually starts with large fields covering all areas at risk to 50 Gy, followed by shrinking fields to boost higher risk areas. The spinal cord is excluded after 40 Gy. A final boost treatment to the primary tumor bed and neck regions with involved lymph nodes may be administered using either EBRT or brachytherapy.</p><p>Retrospective studies suggest that a treatment boost with brachytherapy may improve local control for patients with positive tumor margins [<a href="#rid45">45,46</a>]. However, brachytherapy is used less frequently since the majority of patients with positive margins typically receive chemotherapy concurrently with adjuvant RT, and the brachytherapy catheters must be available to be placed at the time of surgery.</p><p>IMRT typically delivers a dose of 60 Gy in 30 fractions. CTV1 (high-risk areas) gets 60 Gy, CTV2 gets 57 Gy (intermediate-risk operated areas), and CTV3 (non-operated, elective areas, eg, N0 contralateral neck) gets 54 Gy. A boost for extracapsular extension or positive microscopic margins, as described above, can be used to 66 Gy.</p><p class="headingAnchor" id="H541274485"><span class="h2">Adjuvant versus neoadjuvant radiation therapy</span><span class="headingEndMark"> — </span>RT is used almost exclusively as adjuvant therapy for head and neck cancer. Neoadjuvant (eg, preoperative) RT is no longer used due to concerns about operating in an irradiated field, the poorer local control in one older trial, the ability to use pathologic findings to guide high-dose RT planning, and the use of functional organ preservation approaches (chemoradiation). In the RTOG 7303 trial, preoperative RT used a dose of 50 Gy and the local control was worse than adjuvant RT with a dose of 70 Gy [<a href="#rid47">47</a>]. There was no difference in overall survival. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.) </p><p class="headingAnchor" id="H1339502897"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of adjuvant radiation therapy (RT) </strong>– Selected patients with head and neck squamous cell carcinoma treated with primary surgical resection who are at increased risk for locoregional recurrence are treated with adjuvant (ie, postoperative) radiation therapy (RT), with or without concurrent chemotherapy, with the aim of improving locoregional control and survival. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinicopathologic features indicating risk of recurrence </strong>– For patients who have undergone surgery for locoregionally advanced head and neck cancer, we recommend adjuvant RT for those with the following high-risk features (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Approach to adjuvant management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Advanced tumor stage (T3/T4).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive or close margins.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two or more positive lymph nodes (N2/N3).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extranodal extension – There are not enough data to reduce the adjuvant radiation dose or eliminate chemoradiation in patients with human papillomavirus (HPV) associated versus non-HPV associated oropharyngeal cancer.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Perineural or lymphovascular invasion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for adjuvant chemoradiation</strong> – For patients with positive surgical margins or extranodal extension, we suggest adjuvant concurrent chemoradiation rather than adjuvant RT alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We offer this approach regardless of the HPV status of the tumors. (See <a class="local">'Adjuvant chemoradiation'</a> above and  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Adjuvant RT with or without chemotherapy'</a>.)</p><p></p><p class="bulletIndent1">However, further data on the benefits of adjuvant chemoradiation versus adjuvant RT in HPV associated tumors with extranodal extension are necessary, as observational studies are mixed and prospective clinical trials are limited. (See <a class="local">'Approach to adjuvant management'</a> above and  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer", section on 'Is there a role for treatment deintensification?'</a>.)</p><p></p><p class="bulletIndent1">Additionally, data do not show a clear benefit to adding chemotherapy to adjuvant RT for those with two or more positive lymph nodes in the absence of extranodal extension or positive margins. The use of chemotherapy for these patients should be determined on an individual basis, although retrospective data suggest that chemoradiation may provide a survival benefit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients eligible for platinum-based chemotherapy, we recommend weekly <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (40 mg/m<sup>2</sup> weekly) rather than bolus cisplatin (100 mg/m<sup>2</sup> every three weeks for three doses) concurrent with RT (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Platinum-based chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are not candidates for cisplatin-based therapy, we suggest RT alone rather than concurrent chemoradiation with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> or other systemic agents. (See <a class="local">'Carboplatin'</a> above and <a class="local">'Other regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for adjuvant RT </strong>– For patients with an increased risk of recurrence, but without positive surgical margins or extranodal extension, we suggest adjuvant RT without systemic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Adjuvant radiation therapy alone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of adjuvant RT </strong>– In the absence of wound healing issues or medical contraindications, adjuvant RT should be started within six weeks after surgery and completed in a timely manner. (See <a class="local">'Administration'</a> above.)</p><p></p><p class="headingAnchor" id="H1129133837"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Shruti Jolly, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Koyfman SA, Ismaila N, Crook D, et al. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:1753.</a></li><li><a class="nounderline abstract_t">Koyfman SA, Ismaila N, Holsinger FC. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline Summary. J Oncol Pract 2019; 15:273.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on September 15, 2021).</li><li><a class="nounderline abstract_t">Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005; 10:215.</a></li><li><a class="nounderline abstract_t">Jacobs JR, Ahmad K, Casiano R, et al. Implications of positive surgical margins. Laryngoscope 1993; 103:64.</a></li><li><a class="nounderline abstract_t">Laramore GE, Scott CB, Schuller DE, et al. Is a surgical resection leaving positive margins of benefit to the patient with locally advanced squamous cell carcinoma of the head and neck: a comparative study using the intergroup study 0034 and the Radiation Therapy Oncology Group head and neck database. Int J Radiat Oncol Biol Phys 1993; 27:1011.</a></li><li><a class="nounderline abstract_t">Rosenthal DI, Mohamed ASR, Garden AS, et al. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2017; 98:1002.</a></li><li><a class="nounderline abstract_t">Sunkara PR, Graff JT, Cramer JD. Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2023; 149:317.</a></li><li><a class="nounderline abstract_t">Meier JD, Oliver DA, Varvares MA. Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey. Head Neck 2005; 27:952.</a></li><li><a class="nounderline abstract_t">Jäckel MC, Ambrosch P, Christiansen H, et al. Value of postoperative radiotherapy in patients with pathologic N1 neck disease. Head Neck 2008; 30:875.</a></li><li><a class="nounderline abstract_t">Sinha P, Lewis JS Jr, Piccirillo JF, et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012; 118:3519.</a></li><li><a class="nounderline abstract_t">Maxwell JH, Ferris RL, Gooding W, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013; 119:3302.</a></li><li><a class="nounderline abstract_t">An Y, Park HS, Kelly JR, et al. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 2017; 123:2762.</a></li><li><a class="nounderline abstract_t">Shevach J, Bossert A, Bakst RL, et al. Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma. Oral Oncol 2017; 74:56.</a></li><li><a class="nounderline abstract_t">Ma DJ, Price KA, Moore EJ, et al. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. J Clin Oncol 2019; 37:1909.</a></li><li><a class="nounderline abstract_t">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945.</a></li><li><a class="nounderline abstract_t">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937.</a></li><li><a class="nounderline abstract_t">Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27:843.</a></li><li><a class="nounderline abstract_t">Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84:1198.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2023. Available at: https://www.nccn.org/professionals/physician_gls/ https://www.nccn.org/professionals/physician_gls/ (Accessed on November 29, 2023).</li><li><a class="nounderline abstract_t">Trifiletti DM, Smith A, Mitra N, et al. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer. J Clin Oncol 2017; 35:1550.</a></li><li><a class="nounderline abstract_t">Kiyota N, Tahara M, Mizusawa J, et al. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. J Clin Oncol 2022; 40:1980.</a></li><li><a class="nounderline abstract_t">Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36:999.</a></li><li><a class="nounderline abstract_t">Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma. Cancer 2009; 115:2464.</a></li><li><a class="nounderline abstract_t">Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 2014; 32:2486.</a></li><li><a class="nounderline abstract_t">Noronha V, Joshi A, Patil VM, et al. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol 2018; 36:1064.</a></li><li><a class="nounderline abstract_t">Szturz P, Wouters K, Kiyota N, et al. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. Oncologist 2017; 22:1056.</a></li><li><a class="nounderline abstract_t">Spreafico A, Huang SH, Xu W, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 2016; 67:174.</a></li><li><a class="nounderline abstract_t">Oliva M, Huang SH, Xu W, et al. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. Eur J Cancer 2019; 118:112.</a></li><li><a class="nounderline abstract_t">Racadot S, Mercier M, Dussart S, et al. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiother Oncol 2008; 87:164.</a></li><li class="breakAll">Kies MS, Harris J, Rotman MZ, et al. Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234). Int J Radiat Oncol Biol Phys 2009; 75:S14 http://www.redjournal.org/article/S0360-3016(09)01099-2/fulltext (Accessed on July 28, 2014).</li><li><a class="nounderline abstract_t">Kokal WA, Neifeld JP, Eisert D, et al. Postoperative radiation as adjuvant treatment for carcinoma of the oral cavity, larynx, and pharynx: preliminary report of a prospective randomized trial. J Surg Oncol 1988; 38:71.</a></li><li><a class="nounderline abstract_t">Mishra RC, Singh DN, Mishra TK. Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial. Eur J Surg Oncol 1996; 22:502.</a></li><li><a class="nounderline abstract_t">Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 2008; 112:535.</a></li><li><a class="nounderline abstract_t">Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys 1992; 23:737.</a></li><li><a class="nounderline abstract_t">Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998; 40:529.</a></li><li><a class="nounderline abstract_t">Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51:571.</a></li><li><a class="nounderline abstract_t">Mantravadi RV, Haas RE, Liebner EJ, et al. Postoperative radiotherapy for persistent tumor at the surgical margin in head and neck cancers. Laryngoscope 1983; 93:1337.</a></li><li><a class="nounderline abstract_t">Parsons JT, Mendenhall WM, Stringer SP, et al. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys 1997; 39:137.</a></li><li><a class="nounderline abstract_t">Peters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993; 26:3.</a></li><li><a class="nounderline abstract_t">Awwad HK, Lotayef M, Shouman T, et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 2002; 86:517.</a></li><li><a class="nounderline abstract_t">Shah N, Saunders MI, Dische S. A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. Clin Oncol (R Coll Radiol) 2000; 12:392.</a></li><li><a class="nounderline abstract_t">Trotti A, Klotch D, Endicott J, et al. A prospective trial of accelerated radiotherapy in the postoperative treatment of high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1993; 26:13.</a></li><li><a class="nounderline abstract_t">Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol 2016; 120:48.</a></li><li><a class="nounderline abstract_t">Chao KS, Emami B, Akhileswaran R, et al. The impact of surgical margin status and use of an interstitial implant on T1, T2 oral tongue cancers after surgery. Int J Radiat Oncol Biol Phys 1996; 36:1039.</a></li><li><a class="nounderline abstract_t">Beitler JJ, Smith RV, Silver CE, et al. Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control. Int J Radiat Oncol Biol Phys 1998; 40:313.</a></li><li><a class="nounderline abstract_t">Marcial VA, Pajak TF, Kramer S, et al. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin Oncol 1988; 15:39.</a></li></ol></div><div id="topicVersionRevision">Topic 3374 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811281" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30883257" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30883257" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793225" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8421422" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Implications of positive surgical margins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262821" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Is a surgical resection leaving positive margins of benefit to the patient with locally advanced squamous cell carcinoma of the head and neck: a comparative study using the intergroup study 0034 and the Radiation Therapy Oncology Group head and neck database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28721881" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36821132" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16127669" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302275" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Value of postoperative radiotherapy in patients with pathologic N1 neck disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086669" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23797868" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323338" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29103752" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31163012" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128894" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128893" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16161069" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749632" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749632" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475848" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35230884" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8985019" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19280588" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002723" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29220295" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533474" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669504" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31330486" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222010" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222010" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288812" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Postoperative radiation as adjuvant treatment for carcinoma of the oral cavity, larynx, and pharynx: preliminary report of a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076014" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1618666" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486600" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597795" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6621234" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postoperative radiotherapy for persistent tumor at the surgical margin in head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9300748" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482629" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870530" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11202092" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A pilot study of postoperative CHART and CHARTWEL in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482619" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A prospective trial of accelerated radiotherapy in the postoperative treatment of high-risk squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27342249" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8985025" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of surgical margin status and use of an interstitial implant on T1, T2 oral tongue cancers after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457815" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3278390" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
